I
Overview
Iota Biosciences develops tiny, implantable bioelectronic devices that diagnose and treat bodily conditions. Its neural dust platform uses ultrasound to power the implants and carry data, letting devices be millimeter-sized and placed deep inside the body. Unlike traditional implants with batteries and wires, these implants rely on ultrasound for both power and communication, enabling real-time sensing and neuromodulation with minimal invasiveness. The company aims to create devices smaller than a cubic millimeter for closed-loop therapies and partners with pharmaceutical companies to advance clinical development.
Work here?Claim your company
Simplify's take
What believers are saying
- October 2024 IDE opened first-in-human underactive bladder trials in 2025.
- Astellas' 2026 reporting lists iota's implantable bladder device in early feasibility study.
- Mike Woods became CEO in April 2026, signaling dedicated urology execution leadership.
What critics are saying
- The bladder trial is still early feasibility; no efficacy data exists by November 2026.
- Astellas still prioritizes oncology and immunology; iota can lose funding to higher-return programs.
- One failed implant safety event would stall ultrasound bioelectronics and kill iota's platform.
What makes iota Biosciences unique
- Astellas owns iota, giving regulatory, manufacturing, and commercial infrastructure for implantable bioelectronics.
- Ultrasound-powered, battery-free implants enable millimeter-scale devices unreachable by conventional wired stimulators.
- 2024 FDA IDE approval validates bladder-wall stimulation and de-risks the platform.
Help us improve and share your feedback! Did you find this helpful?